Overview

Bioequivalence Study of Neurogabin-M (Gabapentin 400 mg) Capsule With Parketin (Gabapentin 400 mg) Capsules

Status:
Completed
Trial end date:
2013-09-10
Target enrollment:
Participant gender:
Summary
This is a single-dose, two-periods, two-sequence, two-way crossover, single oral dose bioequivalence study.
Phase:
N/A
Details
Lead Sponsor:
University of Karachi
Collaborators:
Center for Bioequivalence Studies and Clinical Research (CBSCR), HEJ Research Institute of chemistry, University of Karachi
Merck Pvt. Ltd, Pakistan
Treatments:
Gabapentin